BioSpace News Archive

Lexaria Bioscience Corp. is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH TM -processed cannabidiol for potential application against hypertension.

Agile Therapeutics, Inc. today announced that management will present and participate at the following virtual investor conferences during the month of September 2021.

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), announced it has partnered with Principal Investigator Dr. Matthew Johnson of Johns Hopkins University on a study evaluating the administration of MYCO-001 with a structured smoking cessation treatment program in nicotine dependent individuals.

Abeona Therapeutics Inc. today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor conferences: Citi’s 16th Annual BioPharma Virtual Conference on September 8-10, 2021

Citius Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories, Ltd.

Infinity Pharmaceuticals, Inc. today announced the appointment of Robert Ilaria, Jr., M.D. as Chief Medical Officer. In addition, Brian Schwartz, M.D., will be transitioning from his role as Consulting Chief Physician to the Infinity Board of Directors.

Catalent, Inc. today announced that members of its executive leadership team will virtually present at the Morgan Stanley 19th Annual Global Healthcare Conference at 1:15 a.m. ET on September 9, 2021.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021.

Arbutus Biopharma Corporation today announced that the Company will participate in the following upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021.

OSE Immunotherapeutics announced that it has received notice of allowance from the United States Patent and Trademark Office for a patent application related to Tedopi®, a combination of neoepitopes, protecting its administration schedule for inducing early T-lymphocyte memory response, used in the treatment of non-small cell lung cancer in HLA-A2 positive patients.